Description:
BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients https://clinicaltrials.gov/ct2/show/NCT00099502 The purpose of this study is to determine - whether treatment with Betaferon / Betaseron (interferon beta-1b) 500 micrograms safe, tolerable and more efficacious than treatment with interferon beta-1b 250 micrograms - whether treatment with Betaferon / Betaseron (interferon beta-1b) tolerable and more efficacious than treatment with Copaxone (Glatiramer Acetate) 20 mg
Link:
https://clinicaltrials.gov/ct2/show/NCT00099502Keywords:
Versions (2)
- 12/11/13 12/11/13 - Martin Dugas
- 8/21/15 8/21/15 - Martin Dugas
Uploaded on:
August 21, 2015
DOI:
To request one please log in.License :
Creative Commons BY 4.0Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Multiple Sclerosis Betaferon/Betaseron NCT00099502
- StudyEvent: Eligibility